D.M. Graham Laboratories

D.M. Graham Laboratories was a pharmaceutical company specializing in the development and manufacture of generic drugs, with a particular focus on controlled substances and analgesics. Based in Hobart, New York, the company operated as a contract manufacturer and a developer of its own generic product line. In 1998, it was acquired by Mallinckrodt for approximately 52 million dollars to strengthen Mallinckrodt's position in the pain management and generic pharmaceutical markets. The facility in Hobart continued to serve as a significant manufacturing site for Mallinckrodt following the acquisition, focusing on the production of dosage-form generic narcotics.